BiomX Inc. (PHGE) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. BiomX Inc. is a clinical-stage biotechnology company developing phage-based therapies to treat bacterial infections, focusing on Cystic Fibrosis (CF) and Diabetic Foot Infections (DFI). The company operates as a single segment and is headquartered in Ness Ziona, Israel. As of November 11, 2025, there were 29,006,165 shares of Common Stock outstanding.
Key Financial Metrics
| Metric (USD in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(9,166) | $(9,642) | $(22,862) | $(3,214) |
| Operating Loss | $(8,536) | $(11,328) | $(23,725) | $(27,838) |
| R&D Expenses (Net) | $(6,122) | $(7,279) | $(16,386) | $(18,281) |
| G&A Expenses | $(2,414) | $(3,248) | $(7,339) | $(8,756) |
| Cash & Equivalents (End of Period) | $6,923 | $23,537 | $6,923 | $23,537 |
| Total Cash & Restricted Cash | $8,069 | $24,651 | $8,069 | $24,651 |
| Net Cash Used in Operating Activities (9M) | $(22,004) | $(30,690) | $(22,004) | $(30,690) |
| Accumulated Deficit | $(203,559) | $(166,184) | $(203,559) | $(166,184) |
Material Changes vs. Prior Period
- Operating Expenses: Operating loss decreased by 25% in Q3 2025 compared to Q3 2024, driven by reduced R&D and G&A expenses. R&D expenses declined primarily due to workforce reductions, lower rent expenses (following a 2024 right-of-use asset impairment), and lower manufacturing costs for the BX004 candidate. G&A expenses decreased due to lower salaries, stock-based compensation, and professional fees.
- Warrant Valuation: The company recorded a loss of $0.7 million from the change in fair value of warrants in Q3 2025, compared to a gain of $20.6 million in Q3 2024. This reversal is attributed to the revaluation of warrants classified as liabilities and new warrant issuances in February 2025.
- Goodwill Impairment: Q3 2024 included a $0.8 million goodwill impairment charge related to the APT acquisition, which did not recur in Q3 2025.
- Liquidity: Cash and cash equivalents decreased significantly from $16.9 million at year-end 2024 to $6.9 million at September 30, 2025, reflecting ongoing operational burn despite financing activities.
Guidance, Outlook, and Risks
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. Current cash resources are estimated to fund operations only into the first quarter of 2026. Additional financing via equity, debt, or grants is required.
- Clinical Developments:
- BX004 (CF): The Phase 2b trial is under a clinical hold by the FDA regarding the third-party nebulizer device used for delivery. The FDA has raised no concerns regarding the drug product itself. Enrollment in the EU continues, with topline results expected in Q1 2026.
- BX211 (DFO): Positive Phase 2 results were announced in March 2025 showing statistically significant ulcer area reduction. The company is prioritizing BX011 for Diabetic Foot Infections (DFI) pending resources.
- Financing Activity: In February 2025, the company raised approximately $5.5 million via a registered direct offering and private placement. In the subsequent period (Oct-Nov 2025), the company sold shares under its ATM agreement raising approximately $1.3 million.
- Risk Factors: Key risks include the prolonged U.S. federal government shutdown (impacting FDA/SEC operations), geopolitical instability in Israel, the clinical hold on BX004, and the inability to raise additional capital on favorable terms.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $8.1 million cash balance to sustain operations through Q1 2026 and the status of any new financing efforts.
- FDA Clinical Hold: Monitor the status of the FDA clinical hold on the BX004 Phase 2b trial and the timeline for its resolution.
- Warrant Liability: Review the impact of warrant revaluations on future earnings, as these are classified as liabilities and create volatility in net income.
- Geopolitical Exposure: Assess the potential impact of ongoing conflicts in the Middle East on the company's Israel-based operations and workforce.
- ATM Utilization: Track the utilization of the At-The-Market (ATM) sales agreement and the average share price achieved in recent sales.